Trial Profile

ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary)
Indications HIV-2 infections
Focus Therapeutic Use
Acronyms VIH-2

Most Recent Events

16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
11 Jul 2016 Status changed from active, no longer recruiting to completed.
11 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com